Sugi Predict

Sugi Predict / Targets / IKBKB

IKBKB

Inhibitor of nuclear factor kappa-B kinase subunit beta · O14920 · IKBKB on Sugi Atlas →

111,213 patent compounds predicted against IKBKB, 68,590 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL91448 SCHEMBL91448 0.52 10/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL70622) 0.53 8/20
SCHEMBL100470 SCHEMBL100470 0.48 8/20
SCHEMBL101575 SCHEMBL101575 0.46 7/20
SCHEMBL84453 SCHEMBL84453 0.54 5/20
SCHEMBL99011 SCHEMBL99011 0.54 3/20
SCHEMBL99690 SCHEMBL99690 0.52 3/20
SCHEMBL99190 SCHEMBL99190 0.51 3/20
SCHEMBL100576 SCHEMBL100576 0.50 3/20
SCHEMBL99868 SCHEMBL99868 0.48 3/20
SCHEMBL94358 SCHEMBL94358 0.45 3/20
SCHEMBL100434 SCHEMBL100434 0.45 3/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL99616) 0.44 3/20
SCHEMBL43146 SCHEMBL43146 0.42 3/20
SCHEMBL79357 SCHEMBL79357 0.39 3/20
SCHEMBL100052 SCHEMBL100052 0.38 3/20
Staurosporine Staurosporine (SCHEMBL8156) 1.00 2/20
Staurosporine Staurosporine (SCHEMBL8157) 1.00 2/20
SCHEMBL79945 SCHEMBL79945 0.67 2/20
Metoprine Metoprine (SCHEMBL3681) 0.54 2/20

Clinical trials — most relevant to IKBKB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease PHASE4COMPLETED
Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk PHASE2/PHASE3COMPLETED
Bradykinin Receptor Antagonism During Cardiopulmonary Bypass PHASE2/PHASE3COMPLETED
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients PHASE1/PHASE2COMPLETED
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma PHASE2COMPLETED
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma PHASE2COMPLETED
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia PHASE2COMPLETED
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation PHASE2ACTIVE_NOT_RECRUITING
Impact of Colchicine and Low-dose Naltrexone on COVID-19 PHASE2COMPLETED
Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma PHASE2UNKNOWN
Sodium Bicarbonate in Cardiac Surgery PHASE2COMPLETED
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma PHASE2COMPLETED
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis PHASE2RECRUITING
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PHASE2COMPLETED
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients PHASE1/PHASE2COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients PHASE2COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma PHASE1/PHASE2WITHDRAWN
Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells PHASE2UNKNOWN
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy nanUNKNOWN
IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients nanCOMPLETED
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
MicroRNAs and Cytokines in Peri-Implantitis Tissue nanUNKNOWN
Magnesium and Vitamin D Combination for Post-COVID Syndrome nanCOMPLETED
Early Regenerative Intervention for Post-Traumatic Osteoarthritis nanUNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a IKBKB binder may also engage these)

ProteinNameSimilarity
Q95KV0 — 1.000 Q95KV0 →
Q6GM53 — 1.000 Q6GM53 →
CHUK Inhibitor of nuclear factor kappa-B kinase subunit alpha 1.000 landscape →
Q9QY78 — 0.998 Q9QY78 →
Q28DZ1 — 0.998 Q28DZ1 →
O88351 — 0.998 O88351 →
Q95KV1 — 0.998 Q95KV1 →
Q60680 — 0.995 Q60680 →
Q5ZJB4 — 0.995 Q5ZJB4 →
Q4G3H4 — 0.994 Q4G3H4 →
Q9Z2R9 — 0.992 Q9Z2R9 →
Q6XUX1 — 0.991 Q6XUX1 →
Q4VSN4 — 0.991 Q4VSN4 →
Q7Z3E5 — 0.990 Q7Z3E5 →
Q8BX57 — 0.990 Q8BX57 →
P70600 — 0.989 P70600 →
Q811U4 — 0.989 Q811U4 →
Q8R4Z9 — 0.989 Q8R4Z9 →
Q2HJE1 — 0.989 Q2HJE1 →
A2CI34 — 0.989 A2CI34 →
Q4TVR5 — 0.988 Q4TVR5 →
Q7TMQ7 — 0.988 Q7TMQ7 →
P10911 — 0.988 P10911 →
Q4R8E0 — 0.988 Q4R8E0 →
Q5R6T6 — 0.988 Q5R6T6 →
KDM5D Lysine-specific demethylase 5D 0.988 landscape →
Q94C95 — 0.988 Q94C95 →
WDR91 WD repeat-containing protein 91 0.987 landscape →
Q4VSN3 — 0.987 Q4VSN3 →
G5EFD2 — 0.987 G5EFD2 →